DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506115-17-00

Enrollment

587

Registered

2024-05-17

Start date

2024-10-14

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal Cancer

Brief summary

Progression-free survival

Detailed description

Quality of Life, Physical Functioning, Grade 3-5 chemotherapy-related toxicity, Overall Survival, Number of completed treatment cycles, Dose reductions during treatment, Unplanned hospitalizations, Cumulative received dosage, Cost-effectiveness

Interventions

DRUGFluorouracil 50 mg/ml Solution for injection/infusion

DRUGCalcium Folinate 10 mg/ml Solution for injection or infusion

DRUGCapecitabine 500 mg Film-coated Tablets

DRUGOxaliplatin 5 mg/ml Concentrate for Solution for infusion

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Quality of Life, Physical Functioning, Grade 3-5 chemotherapy-related toxicity, Overall Survival, Number of completed treatment cycles, Dose reductions during treatment, Unplanned hospitalizations, Cumulative received dosage, Cost-effectiveness	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026